ABCL AbCellera Biologics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1703057 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY92.1%
TTM net income YoY13.6%
TTM EPS YoY15.8%
Revenue 3-yr CAGR10.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-298.0%
Net margin-218.5%
FCF margin-48.4%
EBITDA margin-264.0%
Returns
ROE-14.6%
ROA-10.4%
ROIC (approx.)-18.2%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets29.2%
Debt / equity0.00x
Current ratio12.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue25.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.64M | $4.05M | $8.31M | $44.85M | $8.96M | $17.08M | $4.24M | $5.05M |
| R&D expense | $43.53M | $45.99M | $46.66M | $50.09M | $55.03M | $39.21M | $42.50M | $46.08M |
| SG&A expense | $13.61M | $13.85M | $12.33M | $25.98M | $24.96M | $21.99M | $19.07M | $16.02M |
| Operating income | -$53.31M | -$62.78M | -$57.52M | -$28.58M | -$76.28M | -$49.59M | -$62.66M | -$72.75M |
| Pretax income | -$42.81M | -$58.97M | -$49.54M | -$19.50M | -$68.77M | -$36.34M | -$52.98M | -$46.83M |
| Income tax | -$2.05M | -$3.54M | -$6.37M | -$10.55M | -$11.65M | -$1.62M | -$7.36M | -$12.62M |
| Net income | -$40.76M | -$55.43M | -$43.16M | -$8.95M | -$57.12M | -$34.73M | -$45.62M | -$34.21M |
| EBITDA | -$46.51M | -$55.79M | -$50.68M | -$26.19M | -$71.03M | -$44.12M | -$57.33M | -$70.66M |
| EPS (basic) | -0.13 | -0.18 | -0.14 | — | -0.19 | -0.12 | -0.15 | — |
| EPS (diluted) | -0.13 | -0.18 | -0.14 | — | -0.19 | -0.12 | -0.15 | — |
| Weighted avg. shares (diluted) | 318.05M | 305.56M | 303.07M | — | 298.88M | 298.51M | 297.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $163.80M | $120.06M | $77.06M | $128.51M | $108.16M | $117.44M | $184.27M | $156.32M |
| Receivables | $38.29M | $38.42M | $39.16M | $39.41M | $71.25M | $70.00M | $63.61M | $31.98M |
| Inventory | $7.57M | $7.58M | $7.86M | $6.34M | — | — | — | $0 |
| Current assets | $876.16M | $679.23M | $664.60M | $728.23M | $695.14M | $742.14M | $764.98M | $751.37M |
| Goodwill | $47.81M | $47.81M | $47.81M | $47.81M | $47.81M | $47.81M | $47.81M | $47.81M |
| Intangibles | $38.39M | $36.53M | $37.46M | $38.38M | $39.32M | $40.26M | $41.19M | $42.11M |
| Total assets | $1.50B | $1.31B | $1.31B | $1.36B | $1.36B | $1.40B | $1.34B | $1.36B |
| Current liabilities | $70.47M | $53.19M | $47.29M | $64.31M | $68.80M | $67.02M | $75.40M | $76.61M |
| Total liabilities | $437.36M | $411.56M | $369.03M | $390.05M | $391.95M | $394.99M | $321.23M | $304.47M |
| Shareholders' equity | $1.06B | $896.02M | $938.08M | $966.90M | $964.04M | $1.01B | $1.02B | $1.06B |
| Shares outstanding | 326.33M | 306.47M | 303.95M | 300.60M | 299.01M | 295.76M | 295.76M | 295.76M |
| Cash flow statement | ||||||||
| Operating cash flow | $26.91M | $25.92M | -$33.52M | -$34.74M | -$52.59M | -$32.40M | -$11.55M | -$8.00M |
| Capital expenditure | $1.61M | $2.13M | $3.83M | $9.84M | $8.93M | $13.37M | $10.64M | $15.63M |
| Free cash flow | $25.30M | $23.79M | -$37.35M | -$44.59M | -$61.52M | -$45.77M | -$22.19M | -$23.63M |
| Investing cash flow | -$183.44M | $11.34M | -$25.08M | $75.14M | $36.49M | -$31.81M | $7.93M | $35.70M |
| Financing cash flow | $200.64M | $6.39M | $7.19M | $4.12M | $7.37M | -$3.38M | $5.97M | $4.14M |
| Depreciation & amortization | $6.81M | $6.99M | $6.84M | $2.39M | $5.25M | $5.47M | $5.33M | $2.10M |
| Stock-based compensation | $11.67M | $12.29M | $12.01M | $12.90M | $13.89M | $14.21M | $14.79M | $15.23M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.